عرض بسيط للتسجيلة

المؤلفHmila, Issam
المؤلفVaikath, Nishant N
المؤلفMajbour, Nour K
المؤلفErskine, Daniel
المؤلفSudhakaran, Indulekha P
المؤلفGupta, Vijay
المؤلفGhanem, Simona S
المؤلفIslam, Zeyaul
المؤلفEmara, Mohamed M
المؤلفAbdesselem, Houari B
المؤلفKolatkar, Prasanna R
المؤلفAchappa, Devaya K
المؤلفVinardell, Tatiana
المؤلفEl-Agnaf, Omar M A
تاريخ الإتاحة2023-07-09T07:12:27Z
تاريخ النشر2022-08-01
اسم المنشورThe FEBS Journal
المعرّف10.1111/febs.16376
الاقتباسHmila, I., Vaikath, N. N., Majbour, N. K., Erskine, D., Sudhakaran, I. P., Gupta, V., ... & El‐Agnaf, O. M. (2022). Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit in‐vitro seeded aggregation and toxicity. The FEBS Journal, 289(15), 4657-4673.‏
معرّف المصادر الموحدhttp://hdl.handle.net/10576/45151
الملخصNanobodies (Nbs), the single-domain antigen-binding fragments of dromedary heavy-chain antibodies (HCAb), are excellent candidates as therapeutic and diagnostic tools in synucleinopathies because of their small size, solubility and stability. Here, we constructed an immune nanobody library specific to the monomeric form of alpha-synuclein (α-syn). Phage display screening of the library allowed the identification of a nanobody, Nbα-syn01, specific for α-syn. Unlike previously developed nanobodies, Nbα-syn01 recognized the N-terminal region which is critical for in vitro and in vivo aggregation and contains many point mutations involved in early PD cases. The affinity of the monovalent Nbα-syn01 and the engineered bivalent format BivNbα-syn01 measured by isothermal titration calorimetry revealed unexpected results where Nbα-syn01 and its bivalent format recognized preferentially α-syn fibrils compared to the monomeric form. Nbα-syn01 and BivNbα-syn01 were also able to inhibit α-syn-seeded aggregation in vitro and reduced α-syn-seeded aggregation and toxicity in cells showing their potential to reduce α-syn pathology. Moreover, both nanobody formats were able to recognize Lewy-body pathology in human post-mortem brain tissue from PD and DLB cases. Additionally, we present evidence through structural docking that Nbα-syn01 binds the N-terminal region of the α-syn aggregated form. Overall, these results highlight the potential of Nbα-syn01 and BivNbα-syn01 in developing into a diagnostic or a therapeutic tool for PD and related disorders.
اللغةen
الناشرFEBS PRESS
الموضوعLewy body
Parkinson's disease
aggregated alpha-synuclein
nanobody
العنوانNovel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity.
النوعArticle
الصفحات4657-4673
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة